EICHORCondition: Advanced Solid Tumor · Sponsor: Pathios Therapeutics Pty Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This open label, dose escalation module will evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PTT-4256 in participants with solid tumours using a combination of accelerated dose titration (ADT) and Bayesian Optimal Interval (BOIN) design.
This description comes directly from the study's public registry record.
Debbie Macaro · +44 1235 644 96 · enquiries@pathios.com
Always discuss trial participation with your own doctor first.
| Blacktown Hospital | Blacktown, New South Wales, Australia | Recruiting |
| Scientia Clinical Research | Randwick, New South Wales, Australia | Recruiting |
| Southern Oncology Clinical Research Unit (SOCRU) | Adelaide, South Australia, Australia | Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06634849